Aldosterone- Targeted Therapies for Uncontrolled Hypertension in Chronic Kidney Disease

Pre-registration for:
Aldosterone- Targeted Therapies for Uncontrolled Hypertension in Chronic Kidney Disease

Saturday, April 18, 2026

Hyatt Regency Atlanta
Ballroom Regency V
Hilton Minneapolis
265 Peachtree St. NE
Atlanta, Georgia

Register using the form provided below. Click HERE for additional meeting details.
 
This symposium is an independent program within the Renal Physicians Association (RPA) Annual Meeting. It is NOT part of the offi cial RPA Annual Meeting as planned by the RPA Education Committee. RPA does not endorse nor independently promote any company, program or service provided by our partners. This program is provided for informational purposes and does not necessarily refl ect the viewpoints of the RPA.
Register using the form provided below. Click HERE for additional meeting details.
+ Add a Registration
Security Check *
* Required fields.
Symposium Poster

Program Overview:

Chronic kidney disease (CKD) and high blood pressure (BP) are closely
linked and, when not managed appropriately, can lead to serious
outcomes such as myocardial infarction, stroke, heart failure, and
progression to kidney failure. Among patients with CKD, uncontrolled
hypertension (HTN) is one of the most common modifiable risk factors
for cardiovascular events and CKD progression, regardless of the
cause of CKD. The prevalence of HTN is 67% to as high as 92% among
individuals with CKD; the majority of patients with CKD and HTN do
not achieve BP targets. In a recent World Health Organization report,
62% of deaths from CKD were attributed to elevated systolic BP.
Pathological excess of aldosterone induces HTN by forcing the kidneys
to excessively retain sodium and water, increasing blood volume,
and lowering potassium. Beyond fluid retention, it causes HTN
by increasing vascular resistance, stimulating inflammation, and
promoting vascular/cardiac fibrosis and remodeling. Excessive
aldosterone damages the kidneys; achieving optimal BP control
and mitigating the risk of aldosterone-related adverse events are
cornerstones in the management of patients with HTN and CKD.
Mineralocorticoid receptor antagonists (MRAs), which target the
renin-angiotensin-aldosterone system (RAAS), do not fully inhibit
the deleterious effects of aldosterone and may increase serum
aldosterone concentrations. Highly selective aldosterone synthase
inhibitors (ASIs) have emerged as potential alternatives to MRAs;
ASIs decrease aldosterone synthesis, providing another strategy
to inhibit aldosterone effects without affecting cortisol production.
In this symposium, the role of aldosterone dysregulation in the
pathophysiology of cardiovascular, endocrine, and renal diseases will
be explained. Evidence with currently available MRAs for the treatment
of uncontrolled and resistant hypertension will be interpreted. The
rationale for development of highly selective ASIs will be described, and
emerging data with ASIs for the treatment of hypertension discussed.

Educational Objectives:

Upon completion of this activity, participants should be able to:

  • Describe the role of aldosterone dysregulation in uncontrolled hypertension and poor cardiorenal outcomes
  • Explain the evidence with mineralocorticoid receptor antagonists (MRAs) for the treatment of uncontrolled and resistant hypertension
  • Interpret results of studies with aldosterone synthase inhibitors (ASIs) for the treatment of uncontrolled hypertension

Target Audience:

This program is intended for nephrologists and other clinicians managing patients with hypertension and/or chronic kidney disease.

Accreditation and Credit Designation Statements

Voxmedia, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Voxmedia, LLC designates this live activity for a maximum of 1.0 AMA PRA Category Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Nurse practitioners may participate in this educational activity and earn a certificate of completion as AANP accepts AMA PRA Category 1 Credits™ through its reciprocity agreements. The National Commission on Certification of Physician Assistants accepts AMA PRA Category 1 Credits™ from organizations accredited by the ACCME.

Educational Grant:

Voxmedia International gratefully acknowledges the educational grant provided by AstraZeneca Pharmaceuticals.

Disclosure Information

Voxmedia strives to ensure fair-balance, independence, objectivity, and scientific rigor in all directly or jointly sponsored educational activities. All prospective faculty are required to disclose to Voxmedia all financial relationships for the preceding 24 months (1) with any commercial interest producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients AND (2) with any commercial supporters prior to participating in the planning of an activity or developing content. Only after Voxmedia mitigates all financial relationships may faculty receive approval to participate and are expected to contribute evidence-based material. Faculty are required to indicate areas of their presentation that are based on professional opinion vs. guidelines, meta-analysis. All information submitted will be peer reviewed. The intent of this disclosure is not to prevent faculty from participating, but rather to provide learners with information on which they can make their own judgment of commercial bias. Voxmedia will disclose to learners that all relevant financial relationships have been mitigated in either written materials, visually and/or verbally. It remains for the audience to determine whether the speaker’s interests or relationships may influence the presentation. Speakers must make a meaningful disclosure to the audience of their discussions of any unlabeled or investigational use(s) of drugs or devices.

Americans with Disabilities Act:

Voxmedia fully complies with the legal requirements of the ADA and the rules and regulations thereof. If any participant of this activity is in need of accommodation, please call and/or submit in writing to: Voxmedia, 1 Bethany Rd. Bldg 3, Suite 48, Hazlet, NJ 07730. Phone: 973-467-0500.